Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Moodys
Harvard Business School
Colorcon
McKesson

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SECRETIN

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Secretin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00036231 Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction Terminated Repligen Corporation Phase 3 2002-04-01 The purpose of the study is to determine the effect of multiple doses of secretin on autism.
NCT00036244 Synthetic Human Secretin in Children With Autism Completed Repligen Corporation Phase 3 2002-04-01 The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.
NCT00065962 Secretin for the Treatment of Autism Completed National Institute on Deafness and Other Communication Disorders (NIDCD) Phase 3 1999-06-01 Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00065962 Secretin for the Treatment of Autism Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 3 1999-06-01 Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00216294 Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder Completed Repligen Corporation Phase 2 2005-02-01 The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic Human Secretin) when administered three times weekly to outpatients with obsessive compulsive disorder (OCD), to determine the impact of multiple subcutaneous injections of RG1068 on the symptoms of OCD, as measured by changes in clinical scales, and to evaluate the effect of RG1068 on ODC patients' anxiety, quality of life, and depression.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Secretin

Condition Name

Condition Name for Secretin
Intervention Trials
Chronic Pancreatitis 7
Pancreatic Cancer 5
Autism 3
Healthy Volunteers 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Secretin
Intervention Trials
Pancreatitis 10
Pancreatic Neoplasms 8
Pancreatitis, Chronic 8
Autistic Disorder 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Secretin

Trials by Country

Trials by Country for Secretin
Location Trials
United States 35
United Kingdom 3
Denmark 1
India 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Secretin
Location Trials
Ohio 4
Indiana 4
Massachusetts 4
New Hampshire 3
New York 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Secretin

Clinical Trial Phase

Clinical Trial Phase for Secretin
Clinical Trial Phase Trials
Phase 4 3
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Secretin
Clinical Trial Phase Trials
Completed 12
Recruiting 7
Terminated 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Secretin

Sponsor Name

Sponsor Name for Secretin
Sponsor Trials
Repligen Corporation 6
ChiRhoClin, Inc. 5
Massachusetts General Hospital 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Secretin
Sponsor Trials
Other 30
Industry 13
NIH 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
AstraZeneca
Express Scripts
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.